

MAR 1 6 2005

## **FAX**



GlaxoSmithKilne
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

Attn: Examiner Rao, Deepak, Group 1624 Τo Company USPTO Fax 703-872-9306 From Patty Wilson Tel 1-919-483-1007; Facsimile: 1-919-483-7977 E-mail patricia.t.wilson@gsk.com Date March 16, 2005 Pages including cover 35 Application of: Andrews III et al. Subject U.S. Serial No.: 10/070,084 Filed: August 31, 2000 Title: Benzophenones as Inhibitors of Reverse Transcriptase Attorney Docket No. PU3517USw

Attached:

Amendment Transmittal (26 pgs);

IDS and PTO-1449 (3 pgs) (in duplicate);

Copy of 1 reference (3 pgs).

## Certificate of Transmission by Facsimile (37 CFR 1.8)

I hereby certify that this correspondence is being facsimile transmitted on March 16, 2005.

Patty Wilson

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

P.2/36

MAR 1 6 2005

Serial No. 10/070,084 Docket No. PU3517USw Reply to Office Action of December 16, 2004

Docket No. PU3517USw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Andrews, C.W. et al.

SERIAL NO. 10/070,084

ART UNIT: 1624

FILED:

March 7, 2002

EXAMINER: Deepak R. Rao

FOR:

BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE

Commissioner of Patents P.O. Box 1450 Alexandria VA 22313-1459

## Response under 37 C.F.R. § 1.116

Sir:

In response to the Office action mailed December 16, 2004, please amend the aboveidentified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 26 of this paper.